Registro:

Referencias:

• Bollenbach, T., Antimicrobial interactions: Mechanisms and implications for drug discovery and resistance evolution (2015) Curr. Opin. Microbiol., 27, pp. 1-9
• Sader, H.S., Huynh, H.K., Jones, R.N., Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β-lactams tested against Gram-negative bacilli (2003) Diagn. Microbiol. Infect. Dis., 47, pp. 547-550
• Fung-Tomc, J.C., Gradelski, E., Valera, L., Huczko, E., Bonner, D.P., Synergistic activity of the novel desfluoro (6) quinolone, garenoxacin (BMS-284756), in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species (2002) Int. J. Antimicrob. Agents, 20, pp. 57-60
• Mandal, S., Mandal, M., Pal, N.K., In vitro efficacy of ciprofloxacin alone and in combination with amoxycillin against Salmonella typhi isolates (2003) Indian J. Exp. Biol., 41, pp. 360-362
• Chen, Y.H., Peng, C.F., Lu, P.L., Tsai, J.J., Chen, T.P., In vitro activities of antibiotic combinations against clinical isolates of Pseudomonas aeruginosa (2004) Kaohsiung J. Med. Sci., 20, pp. 261-267
• Al-Hasan, M.N., Wilson, J.W., Lahr, B.D., Thomsen, K.M., Eckel-Passow, J.E., Vetter, E.A., Tleyjeh, I.M., Baddour, L.M., β-Lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by Gram-negative bacilli (2009) Antimicrob. Agents Chemother., 53, pp. 1386-1394
• Hernández, A., Sanchez, M.B., Martinez, J.L., Quinolone resistance: Much more than predicted (2011) Front Microbiol., 2, pp. 1-6
• Blondeau, J.M., Fluoroquinolones: Mechanism of action, classification, and development of resistance (2004) Surv. Ophthalmol., 49, pp. S73-S78
• Pommier, Y., Leo, E., Zhang, H., Marchand, C.H., DNA topoisomerases and their poisoning by anticancer and antibacterial drugs (2010) Chem. Biol., 17, pp. 421-433
• Hooper, D.C., Mechanisms of action of antimicrobials: Focus on fluoroquinolones (2001) Clin. Infect. Dis., 32, pp. S9-S15
• Fournier, B., Zhao, X., Lu, T., Drlica, K., Hooper, D., Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: Different patterns of quinolone-induced inhibition of DNA synthesis (2000) Antimicrob. Agents Chemother., 44, pp. 2160-2165
• Fournier, B., Hooper, D., Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: Novel pleiotropic effects on quinolone and coumarin activity (1998) Antimicrob. Agents Chemother., 42, pp. 121-128
• Aldred, K.J., Kerns, R.J., Osheroff, N., Mechanism of quinolone action and resistance (2014) Biochemistry, 53, pp. 1565-1574
• Shen, L.L., Mitscher, L.A., Sharma, P.N., O'Donnell, T.J., Chu, W.T., Cooper, C.S., Rosen, T., Pernet, A.G., Mechanism of inhibition of DNA gyrase by quinolone antibacterials: A cooperative drug-DNA binding model (1989) Biochemistry, 28, pp. 3886-3894
• Pali, G., Valisena, S., Ciarrocchi, G., Gatto, B., Palumbo, M., Quinolone binding to DNA is mediated by magnesium ions (1992) Proc. Natl. Acad. Sci. U.S.A., 89, pp. 9671-9675
• Fan, J.Y., Sun, D., Yu, H., Kerwin, S.M., Hurley, L.H., Self-assembly of a quinobenzoxazine-Mg2+ complex on DNA: A new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex (1995) J. Med. Chem., 38, pp. 408-424
• Llorente, B., Leclerc, F., Cedergren, R., Using SAR and QSAR analysis to model the activity and structure of the quinolone-DNA complex (1996) Bioorg. Med. Chem., 4, pp. 61-71
• Heddle, J.G., Barnard, F.M., Wentzell, L.M., Maxwell, A., The interaction of drugs with DNA gyrase: A model for the molecular basis of quinolone action (2000) Nucleosides Nucleotides Nucleic Acids, 19, pp. 1249-1264
• Pinto Vitorino, G., Sperandeo, N.R., Caira, M.R., Mazzieri, M.R., A supramolecular assembly formed by heteroassociation of ciprofloxacin and norfloxacin in the solid state: Co-crystal synthesis and characterization (2013) Cryst. Growth Des., 13, pp. 1050-1058
• Fabbiani, F.P., Arlin, J.B., Buth, G., Dittrich, B., Florence, A.J., Herbst-Irmer, R., Sowa, H., Intermolecular interactions, disorder and twinning in ciprofloxacin-2,2-difluoroethanol (2/3) and ciprofloxacin-water (3/14.5) (2011) Acta Crystallogr. C, 67, pp. o120-o124
• Mafra, L., Santos, S.M., Siegel, R., Alves, I., Almeida Paz, F.A., Dudenko, D., Spiess, H.W., Packing interactions in hydrated and anhydrous forms of the antibiotic ciprofloxacin: A solid-state NMR, X-ray diffraction, and computer simulation study (2012) J. Am. Chem. Soc., 134, pp. 71-74
• Becerra, M.C., Eraso, A., Albesa, I., Comparison of oxidative stress induced by ciprofloxacin and pyoverdin in bacteria and in leukocytes to evaluate toxicity (2003) Luminescence, 18, pp. 334-340
• Becerra, M.C., Albesa, I., Oxidative stress induced by ciprofloxacin in Staphylococcus aureus (2002) Biochem. Biophys. Res. Commun., 297, pp. 1003-1007
• Dwyer, D.J., Kohanski, M.A., Hayete, B., Collins, J.J., Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli (2007) Mol. Syst. Biol., 3, p. 91
• Breda, S.A., Jimenez-Kairuz, A.F., Manzo, R.H., Olivera, M.E., Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives (2009) Int. J. Pharm., 371, pp. 106-113
• Dalhoff, A., Global floroquinolone resistance epidemiology and implications for clinical use (2012) Interdiscip. Perspect. Infect. Dis., 2012, pp. 1-37
• Redgrave, L.S., Sutton, S.B., Webber, M.A., Piddock, L.J., Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success (2014) Trends Microbiol., 22, pp. 438-445
• Fish, D.N., Fluoroquinolone adverse effects and drug interactions (2001) Pharmacotherapy, 21, pp. 253S-272S
• Leone, R., Venegoni, M., Motola, D., Moretti, U., Piazzetta, V., Cocci, A., Resi, D., Conforti, A., Adverse drug reactions related to the use of fluoroquinolone antimicrobials: An analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions (2003) Drug Saf., 26, pp. 109-120
• Liu, H.H., Safety profile of the fluoroquinolones (2010) Focus on Levofloxacin. Drug Saf., 33, pp. 353-369
• Isenberg, H.D., Synergism testing: Broth microdilution checkerboard and broth macrodilution methods (1992) Clinical Microbiology Procedures Handbook, 1, pp. 5161-5181. , Anon, American Society for Microbiology, Washington
• Guerillot, F., Carret, G., Flandrois, J.P., Mathematical model for comparison of time-killing curves (1993) Antimicrob. Agents Chemother., 37, pp. 1685-1689
• Ozaki, M., Segawa, J., Kitano, M., Tomii, Y., Honmura, T., Matsuda, M., Kise, M., Nishino, T., Structure-antibacterial activity and cytotoxicity relationships of thiazolo and thiazetoquinolone derivatives (1996) Biol. Pharm. Bull., 19, pp. 1457-1462
• Kim, J., Yoon, Y.H., Cho, I.H., Lee, J.M., Lee, K., Kim, J.E., Hong, K.H., Synthesis and antibacterial activity of a new series of quinolones with 7-substituent of [3.1.1]bicyclic amines (1996) Korean J. Med. Chem., 6, pp. 183-189
• Fung-Tomc, J.C., Gradelski, E., Valera, L., Kolek, B., Bonner, D.P., Comparative killing rates of fluoroquinolones and cell wall-active agents (2000) Antimicrob. Agents Chemother., 44, pp. 1377-1380
• Eliopoulos, G.M., Moellerig, R.C., Antimicrobial combinations (1996) Antibiotics in Laboratory Medicine, pp. 331-338. , (Lorian V ed.). Williams & Wilkins Co., U.S.A
• Belley, A., Neesham-Grenon, E., Arhin, F.F., McKay, G.A., Parr, T.R., Jr., Moeck, G., Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus (2008) Antimicrob. Agents Chemother., 52, pp. 3820-3822
• Doern, C.D., When does 2 plus 2 equal 5? A review of antimicrobial synergy testing (2014) J. Clin. Microbiol., 52, pp. 4124-4128
• Balaji, V., Jeremiah, S.S., Baliga, P.R., Polymyxins: Antimicrobial susceptibility concerns and therapeutic options (2011) Indian J. Med. Microbiol., 29, pp. 230-242
• Dwyer, D., Belenky, P., Yang, J., MacDonald, I.C., Martell, J., Takahashi, N., Chan, C., Collins, J.J., Antibiotics induce redox-related physiological alterations as part of their lethality (2014) Proc. Natl. Acad. Sci. U.S.A., 111, pp. E2100-E2109
• Belenky, P., Ye, J.D., Porter, C.B., Cohen, N.R., Lobritz, M.A., Ferrante, T., Jain, S., Collins, J.J., Bactericidal antibiotics induce toxic metabolic perturbations that lead to cellular damage (2015) Cell Reports, 13, pp. 968-980
• Kottur, J., Nair, D.T., Reactive oxygen species play an important role in the bactericidal activity of quinolone antibiotics (2016) Angew. Chem. Int. Ed. Engl., 55, pp. 2397-2400
• Masadeh, M.M., Alzoubi, K.H., Al-Azzam, S.I., Khabour, O.F., Al-Buhairan, A.M., Ciprofloxacin-induced antibacterial activity is atteneuated by pretreatment with antioxidant agents (2016) Pathogens, 5, p. 28
• Saveta Popa, D., Kiss, B., Vlase, L., Iepure, R., Loghin, F., Different patterns of oxidative stress generation for ciprofloxacin and norfloxacin (2007) Toxicol. Lett., 172 S, p. S25
• Barnes, A.I., Herrero, I., Albesa, I., New aspect of the synergistic antibacterial action of ampicillin and gentamicin (2005) Int. J. Antimicrob. Agents, 26, pp. 146-151
• Molina-Quiroz, R.C., Loyola, D., Muioz-Villagrán, C., Quatrini, R., Vásquez, C., Pirez-Donoso, J., DNA, cell wall and general oxidative damage underlie the tellurite/cefotaxime synergistic effect in Escherichia coli (2013) PLOS ONE, 8, p. e79499
• Smirnova, G.V., Tyulenev, A., Muzyka, N., Peters, M., Oktyabrsky, O., Ciprofloxacin provokes SOS-dependent changes in respiration and membrane potential and causes alterations in the redox status of Escherichia coli (2017) Res. Microbiol., 168, pp. 64-73

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------